Academy of Marketing Science Mary Kay Doctoral Dissertation Awards Announced at 2021 Annual Conference
27.7.2021 16:03:00 EEST | Business Wire | Press release
Mary Kay Inc., a leading corporate advocate of women’s empowerment and entrepreneurship, continued its decades-long support of education and research with the announcement of the 2021 winners of the Mary Kay Doctoral Dissertation and Doctoral Dissertation Proposal Awards at the Academy of Marketing Science (AMS) Annual Conference held virtually last month. For more than 25 years, the global beauty company has awarded these annual grants to provide doctoral candidates in marketing the opportunity to showcase their successfully defended dissertations in front of their peers. Finalists are selected based on their final presentations at the AMS Annual Conference.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005230/en/
AMS Mary Kay Doctoral Dissertation Awards were presented to six deserving winners at the 2021 AMS Annual Conference held virtually. (Graphic: Mary Kay Inc.)
Submissions are open to doctoral students from programs at any recognized university, college of higher learning, business school or management school worldwide. The finalists of the 2021 Mary Kay Doctoral Dissertation and Doctoral Dissertation Proposal Awards are:
2021 Mary Kay Doctoral Dissertation Proposal Award Finalists
- Winner – Luo Bowen, PhD Candidate, University of Rochester, United States
- 1st Runner Up – Aleksandrina Atanasova, PhD Candidate, Royal Holloway University of London, United Kingdom
- 2nd Runner Up – Riley Krotz, PhD Candidate, University of Tennessee, United States
2021 Mary Kay Doctoral Dissertation Award Finalists
- Winner – Irene Nahm, PhD, University of Minnesota, United States
- 1st Runner Up – Constant Pieters, PhD, Tilburg University, Netherlands
- 2nd Runner Up – Victor Lima, PhD, York University, Canada
“Mary Kay is committed to providing opportunities for empowerment, career advancement and education globally,” said Sheryl Adkins-Green, Chief Marketing Officer at Mary Kay Inc. “Supporting marketing professionals through the Academy of Marketing Science Dissertation and Dissertation Proposal Awards allows remarkable individuals to shine and advance their careers. They are making tremendous contributions to the field of marketing and we are honored to be able to support them in their pursuits.”
“Each year, we receive dozens of submissions for the Mary Kay Dissertation Awards from marketing professionals looking to advance their career and receive critical feedback from their peers to help strengthen their dissertation,” said Julie Moulard, President of Academy of Marketing Science. “For over two decades, Mary Kay’s Dissertation Awards have provided opportunities to structure and fine-tune their research, network with industry leaders, and increase visibility among their academic colleagues, which are all crucial to further substantiating their work and publishing their findings in credible marketing journals.”
For more information about the Academy of Marketing Science Mary Kay Dissertation Awards, click here.
About Mary Kay
One of the original glass ceiling breakers, Mary Kay Ash founded her beauty company nearly 60 years ago with three goals: develop rewarding opportunities for women, offer irresistible products, and make the world a better place. That dream has blossomed into a multibillion-dollar company with millions of independent sales force members in nearly 40 countries. Mary Kay is dedicated to investing in the science behind beauty and manufacturing cutting-edge skin care, color cosmetics, and fragrances, and partnering with organizations from around the world to drive a positive social impact. The Mary Kay Global Design Studio is the in-house creative agency serving as the creative incubator for Mary Kay’s fashion, designer and influencer collaborations and branding campaigns, to transform product and packaging design and consumer-facing digital innovation.
About The Academy of Marketing Science
The Academy of Marketing Science is a non-profit, international, scholarly, professional organization. It is dedicated to promoting high standards and excellence in the creation and dissemination of marketing knowledge and the furtherance of marketing practice through a role of leadership within the discipline of marketing around the world. The Academy is committed to the highest ethical standards and collegiality in the pursuit of this mission.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005230/en/
Contact information
Mary Kay Inc. Corporate Communications
Marykay.com/newsroom
(+1) 972.687.5332 or media@mkcorp.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom